9月3日下午
Cetuximab (Erbitux) in NSCLC: How to select patients to obtain maximum treatment benefit
(西妥昔单抗[爱必妥]治疗非小细胞肺癌: 如何选择患者以获得最佳疗效)
Therapy for NSCLC patients with EGFR mutations: Consensus in China
(EGFR突变的非小细胞肺癌治疗策略: 中国专家共识)
Acquied resistance and its therapy of EGFR TKI
(EGFR-TKI治疗及其获得性耐药)
Treatment after failure of EGFR TKI in lung cancer
(肺癌中EGFR-TKI治疗失败后的措施)
NSCLC: Recent developments in anti-angiogenic therapies
(非小细胞肺癌中抗血管生成治疗的新进展)
Lung Cancer: Primary endpoints and the implications for the design of clinical studies
(肺癌临床研究的首要终点及其对研究设计的影响)
Thymic tumors: Diagnostic controversies and difficulties
(胸部肿瘤诊断的争论和困境)
Lung Cancer: Challenges and potential solutions for response assessment by imaging in clinical studies
(肺癌临床研究中肿瘤评价的影像分析的挑战和解决方法)
Lung Cancer: From tissue to molecular phenotyping——pre-analytical requirements
(从组织到分子分型: 分析前标准)
编辑: belinda_1231 作者:丁香园通讯员
以下网友留言只代表网友个人观点，不代表网站观点
